Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Endocarditis I: Introduction01:25

Endocarditis I: Introduction

Introduction:Endocarditis is the infection of the endocardium, the inner lining of the heart and its valves. When the heart muscle is involved, the condition is termed myocarditis, while an infection of the outer lining is called pericarditis. Infective endocarditis (IE) primarily affects the endocardium, where pathogens adhere to the valves or lining, forming vegetation that can lead to severe complications. Infective endocarditis occurs when microorganisms, usually bacteria from other body...
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A mutation in PTPN6 associated to emphysema alters B-lymphocyte biology in humans and mice.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

NuMA1 controls myonuclear motility in striated skeletal muscle through AMPK activity and is impaired in Duchenne muscular dystrophy.

Cell death & disease·2026
Same author

Scope and Outcome of Early Repolarization Syndrome in Unexplained Cardiac Arrest: Insights From the National HiRO Registry.

Circulation. Arrhythmia and electrophysiology·2026
Same author

Genome and Transcriptome-Wide Analyses Identify Multiple Candidate Genes and a Significant Polygenic Contribution in Bicuspid Aortic Valve.

Circulation·2026
Same author

Integrative genetic and liver transcriptomic analyses identify TRIB1AL as a target for steatotic liver disease.

The Journal of clinical endocrinology and metabolism·2026
Same author

Genomic and transcriptomic analyses of aortic stenosis enhance therapeutic target discovery and disease prediction.

Nature genetics·2025

Related Experiment Video

Updated: May 12, 2026

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
10:53

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents

Published on: July 3, 2013

20.4K

Circulating Autoantibodies Targeting TREK-1 in Patients With Short-Coupled Ventricular Fibrillation.

Jin Li1, Alexandre Janin2,3, Mona Patoughi2

  • 1Department of Physiology, University of Bern, Switzerland (J.L.).

Circulation
|September 24, 2024
PubMed
Summary

Short-coupled ventricular fibrillation (SCVF) is linked to autoantibodies against the cardiac TREK-1 channel. These autoantibodies may play a direct role in causing SCVF, offering a potential biomarker for this condition.

Keywords:
TREK-1autoantibodyautoimmunityshort-coupled ventricular fibrillation

More Related Videos

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

17.3K
Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
12:46

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells

Published on: August 17, 2022

2.5K

Related Experiment Videos

Last Updated: May 12, 2026

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents
10:53

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents

Published on: July 3, 2013

20.4K
Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

17.3K
Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
12:46

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells

Published on: August 17, 2022

2.5K

Area of Science:

  • Cardiology
  • Immunology
  • Electrophysiology

Background:

  • Short-coupled ventricular fibrillation (SCVF) is an emerging electrical disorder causing unexplained cardiac arrest.
  • The underlying pathophysiology of SCVF is not well understood, with genetic factors not fully explaining the condition.
  • Autoimmune mechanisms have not been previously investigated as a potential cause of SCVF.

Purpose of the Study:

  • To investigate the presence of circulating autoantibodies in SCVF patients.
  • To determine if identified autoantibodies contribute to the arrhythmogenesis of SCVF.

Main Methods:

  • A prospective case-control study involving cardiac arrest survivors with SCVF or idiopathic ventricular fibrillation (IVF).
  • Plasma samples were analyzed for autoantibodies against cardiac ion channels using peptide microarray technology.
  • Functional studies using patch clamp electrophysiology were performed on identified autoantibodies.

Main Results:

  • Autoantibodies targeting the cardiac TREK-1 channel were found in 50% of SCVF patients (P=0.049).
  • These anti-TREK-1 autoantibodies demonstrated channel-activating properties in cellular models.
  • The arrhythmogenic effects of anti-TREK-1 autoantibodies were inhibited by quinidine.

Conclusions:

  • SCVF patients possess circulating autoantibodies against the cardiac TREK-1 channel.
  • Anti-TREK-1 autoantibodies represent the first identified biomarker for SCVF.
  • These autoantibodies are implicated in the arrhythmogenesis of SCVF.